Copyright
©The Author(s) 2015.
World J Hepatol. Mar 27, 2015; 7(3): 521-531
Published online Mar 27, 2015. doi: 10.4254/wjh.v7.i3.521
Published online Mar 27, 2015. doi: 10.4254/wjh.v7.i3.521
Table 6 Overall survival of patients using the ART score calculated before the third TACE with a cut-off value of: 0-1.5 vs≥ 2.5
| ART(n = 126) | ART[0](n = 73) | ART[1](n = 12) | ART[1.5](n = 6) | ART[2.5](n = 4) | ART[4](n = 21) | ART[5](n = 2) | ART[6.5](n = 4) | ART[7](n = 2) | ART[8](n = 2) |
| Median-survival, mo (95%CI) | 35 (30-37) | 12 (10-18) | 34 (27-38) | 13 (8-24) | 28 (19-41) | 21 (9-32) | 8 (5-9) | 28 (25-31) | 6 (4-8) |
| 31 (27-36) | 21 (13-28) | ||||||||
| P value ART (0, 1.5) vs ART ≥ 2.5 | 0.004 | ||||||||
- Citation: Adhoute X, Penaranda G, Castellani P, Perrier H, Bourliere M. Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system? World J Hepatol 2015; 7(3): 521-531
- URL: https://www.wjgnet.com/1948-5182/full/v7/i3/521.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i3.521